
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, creating an attractive entry point.
Bio-Techne reported fourth-quarter adjusted earnings of 53 cents. It beat the consensus of 50 cents. Sales reached $316.96 million, beating the consensus of $316 million.